Medical Oncologist
CION Cancer Clinics
Is HIPEC worth it? What the evidence actually shows | CION Cancer Clinics
For some cancers the evidence says yes, for others it says no or not yet. HIPEC is well established for pseudomyxoma and appendix tumours, supported in one specific ovarian cancer setting, and still debated for colorectal and gastric spread. In every study, complete removal of visible disease matters more than the heated chemotherapy. This page explains what the trials found and what your team weighs. CION Cancer Clinics’ surgical oncologists in Hyderabad can talk this through with you.
MM
Medically reviewed by Dr. Muralidhar MuddusettyConsultant Surgical Oncologist · MBBS (AIIMS), MS (Surgery, AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Is HIPEC worth it?
- What does the evidence show for each cancer?
- Words you will meet when you read about the evidence
- What does your team weigh before recommending it?
- Four things families say about HIPEC, and what is actually true
- What this page cannot tell you
- Common questions about whether HIPEC is worth it
The short answer
Is HIPEC worth it?
For some cancers and some patients, the evidence says yes; for others it says no, or not yet. Whether it is worth it for you depends on which cancer has spread to the lining of the abdomen, how much of it there is, and whether a surgeon can remove every visible deposit first. Those three facts matter more than the heated chemotherapy itself.
Why the surgery matters more than the heat
HIPEC is never given alone. It follows cytoreductive surgery, the long operation that strips tumour deposits off the lining of the abdomen. In every study that has looked, the completeness of that surgery is what shapes the result. The warmed chemotherapy is meant to deal with cells too small to see. It cannot make up for disease left behind.
What "worth it" has to be weighed against
This is one of the largest operations in cancer surgery: a long anaesthetic, days in intensive care, weeks of recovery and a real chance of a serious complication. So the question is never simply "does it help". It is "does the likely gain, for this cancer, justify that cost to the body".
This page does not tell you whether to have the operation. That decision is made with your surgical oncologist, with your own reports in front of you.Cancer by cancer
What does the evidence show for each cancer?
Pseudomyxoma and appendix tumours
This is where the operation began and where it is most accepted. Because the condition is rare, the evidence comes from large centre series rather than randomised trials, but complete cytoreduction with HIPEC is treated as the standard approach worldwide.
Ovarian cancer
A randomised trial in the Netherlands found that adding HIPEC to surgery done after initial chemotherapy improved outcomes in the group studied. Guidelines differ on whether it should be routine, and further trials are running. Many centres offer it in that specific setting only.
Colorectal peritoneal spread
A large French trial found that adding HIPEC to complete surgery did not improve outcomes over the surgery alone. The surgery still helped. Some centres use a different drug and approach, so the question is still argued. Ask which view your team holds.
Gastric cancer
The evidence is smaller and still being gathered. HIPEC is being studied both to treat spread to the lining and to prevent it after surgery. Outside a trial, most teams reserve it for selected patients with limited disease.
Peritoneal mesothelioma
Rare, and with few other treatments that work well. Cytoreduction with HIPEC is widely used as the main treatment on the strength of centre series rather than randomised trials.
For every cancer here, the evidence applies to disease confined to the abdomen. Spread beyond it changes the answer.Not sure whether this applies to you?
Ask an oncologistIn the studies
Words you will meet when you read about the evidence
- Randomised trial
- A study where patients are allocated by chance to one treatment or another, so the two groups can be fairly compared. It is the strongest kind of evidence, and for rare cancers it often does not exist.
- Complete cytoreduction
- No visible tumour left at the end of surgery. Written as CC-0 on the operation note. This is the single strongest factor in every study.
- PCI
- The Peritoneal Cancer Index, a score for how much of the abdomen is involved. A higher score means more disease and a harder operation.
- Progression-free
- The time during which the cancer has not grown or returned on scans. Trials often report this alongside how long people live overall.
- Quality of life
- How people actually feel and function after treatment, measured by questionnaires. Increasingly reported, because a longer time with a poor recovery is not the same as a better result.
How the decision is made
What does your team weigh before recommending it?
Which cancer, and how it behaves
The starting point is the biopsy. A slow-growing appendix tumour and an aggressive stomach cancer lead to very different conversations, even with the same amount of spread.
How much disease, and where
Scans, and sometimes a keyhole look inside, give the PCI score and show whether the small bowel is heavily involved. Disease outside the abdomen usually rules the operation out.
Whether it can all be removed
The team asks whether complete cytoreduction is realistic. If the honest answer is no, the heated chemotherapy adds risk without the benefit the studies describe.
Whether you can recover from it
Age on its own is not the issue. Heart, lung and kidney function, nutrition and how much treatment you have already had decide whether the body can take the operation and the weeks after it.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
Four things families say about HIPEC, and what is actually true
"HIPEC is the last hope, so it must be worth trying."
It is a treatment with a defined place, not a rescue for every situation. Where the disease cannot all be removed, or has spread beyond the abdomen, the operation adds suffering without the gain seen in studies. A team that says no is often protecting you.
"The heated chemotherapy is the clever part."
The surgery is the part that carries the benefit in every study. The heated wash is an addition, and in at least one large trial it added nothing on top of complete surgery. Ask how much of the expected gain your surgeon puts on each half.
"If the big hospitals abroad do it, the evidence must be settled."
It is settled for some cancers and openly debated for others. Respected centres disagree about colorectal and gastric disease. A surgeon who says the evidence is mixed is being accurate.
"Normal chemotherapy would do the same job with less risk."
Chemotherapy given through a vein reaches the lining of the abdomen poorly, which is why disease there is hard to control. For some patients it is still the better choice.
Did you know
Every case at CION is discussed at a tumour board before a plan is confirmed, so a recommendation for or against a major operation is not one doctor's opinion.
Being straight with you
What this page cannot tell you
It cannot tell you how long anyone will live, with or without the operation. Those figures exist in the studies, but they describe groups of patients chosen under trial rules, and they do not transfer to one person reading on a phone.
It cannot tell you whether your disease is removable
That answer comes from your scans, sometimes from a keyhole look inside, and finally from what the surgeon finds on the day. A plan can change in the operating theatre if more disease is found than expected. Ask beforehand what will happen in that case.
What to ask your surgeon
Ask what the evidence shows for your cancer specifically. Ask what the PCI score is and whether complete removal is realistic. Ask what the alternative plan would be, and how many of these operations the team does each year. Bring the family member who will be caring for you, and write the answers down.
If you would like the evidence explained for your own reports, call the helpline and ask for a surgical oncology consultation.Questions we are asked
Common questions about whether HIPEC is worth it
Does HIPEC actually work, or is it experimental?
Both, depending on the cancer. For pseudomyxoma and appendix tumours it is the accepted standard. For ovarian cancer in one specific setting a randomised trial supports it. For colorectal and gastric spread the evidence is mixed and still being gathered.
Why did one hospital recommend HIPEC and another say no?
Because for some cancers the evidence genuinely divides experienced surgeons, and because the amount of disease on the scan can be read differently. Ask each team which studies they are relying on. A second opinion is reasonable for an operation of this size.
Is it worth it at an older age?
Age alone does not decide it. Fitness does. A person in their seventies with a strong heart, good kidneys and good nutrition may recover well; a younger person weakened by months of chemotherapy may not. The team will test fitness before offering the operation, and will say plainly if the risk is too high.
What happens if the surgeon cannot remove everything?
The plan changes. Many teams will not give the heated chemotherapy if a lot of visible disease has to be left behind, because the evidence for benefit is weak in that situation. Ask before the operation what the team will do if they find more than the scans showed.
Is HIPEC better than ordinary chemotherapy for spread in the abdomen?
Not better in general, different. Chemotherapy through a vein reaches the lining of the abdomen poorly, which is the argument for the operation. But surgery this large is only justified when the disease can all be removed and the body can recover. For many people, chemotherapy or newer drugs remain the right choice.
Can HIPEC be repeated if the cancer comes back?
Sometimes, for pseudomyxoma and a few other slow cancers, a second operation is done. It is harder than the first because of scarring, and the decision follows the same questions: how much disease, where it is, and whether the body can take it. It is uncommon for the faster cancers.
Does having HIPEC mean no more chemotherapy afterwards?
Not always. Depending on the cancer and what the pathology report shows, chemotherapy through a vein may still be recommended after recovery. The operation deals with the abdomen; it does not treat the rest of the body. Ask what the full plan looks like, not only the surgery.
How do I get an honest opinion on whether it suits me?
Take every report and scan to a surgical oncologist who does this operation regularly, and ask them to say plainly which group the evidence puts you in. Then ask what they would recommend if the answer were no. A team that has a clear alternative plan is one that is thinking about you, not the operation.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- NICE — Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (IPG688)
- National Cancer Institute — Surgery to treat cancer
- Cancer Research UK — Pseudomyxoma peritonei
- Cancer.Net — Ovarian, fallopian tube and peritoneal cancer
- American Cancer Society — Colorectal cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Which Cancers Are Treated With HIPECThe cancers where the operation has a defined placeWho Is Eligible for HIPEC?The tests and scores that decide whether it is offeredComplication Rates After HIPEC: The Honest PictureThe other side of the balanceThe Peritoneal Cancer Index (PCI) ExplainedThe score your surgeon will quoteDeciding on Cancer SurgeryHow to weigh any major operation with your family
Talk to us
Want the evidence explained for your own reports?
Send us the biopsy and scan reports or call the helpline. A surgical oncologist will tell you which group the evidence puts you in, and what the alternative would be. One helpline serves every CION centre.